Sun Pharmaceutical Industries Ltd (SPIL) and its executives, including its MD Dilip Shanghvi, have settled a case with capital market regulator SEBI over alleged fund diversion by the company and its subsidiary Sun Pharmaceutical Laboratories .
Whistle blower complaints alleged that transactions with AML were ongoing for several years, but it was disclosed as a related party of SPIL only in FY 2017-18.The